evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

12 questions · 12 findings · 2 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 12 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    over 3 months
    SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
    2 studies
    GRADE not reported

Topical bleomycin vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 3 months
    SoF 5, Safety of the intervention up to 3 months: 'All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was…
    1 study
    GRADE not reported

Systemic beta carotene or carotenoids (incl. lycopene) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    5 to 12 months
    SoF 2, Safety of the intervention at 5 to 12 months: 'Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d (Nagao), and caused adverse effects of varying severity in 9% of…
    3 studies
    GRADE not reported

Herbal extracts (tea components; Chinese herbal mixture; freeze-dried black raspberry gel) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 3 months
    SoF 4, Safety of the intervention up to 3 months: '3 studies measured adverse effects: green tea extract capsules caused high frequency (93%) of adverse effects of varying severity in 1 study; the mixed tea study did…
    3 studies
    GRADE not reported

Vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic acid, acitretin) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    4 to 12 months
    SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
    4 studies
    GRADE not reported

Bowman-Birk inhibitor vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 6 months
    SoF 6, Safety of the intervention up to 6 months: 'Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the…
    1 study
    GRADE not reported

Systemic interventions (aciclovir, thalidomide, corticosteroids, rebamipide, etanercept, colchicine, interferon-alpha) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF 2 (systemic interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim; the review's wording "topical" is a typo for systemic): "8 placebo-controlled trials evaluated topical…
    Studies not reported
    GRADE not reported

Cyclosporin (systemic; 10 mg/kg/day for 16 weeks) vs Colchicine (systemic; 1 mg daily)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review

Topical interventions (sucralfate, interferon-alpha, cyclosporin A) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
    Studies not reported
    GRADE not reported

Thalidomide (systemic; 100 mg or 300 mg daily) vs placebo

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Males only
    Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
    1 study · 101 participants
    GRADE not reported

Interferon-alpha (systemic) vs Placebo (subcutaneous)

Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
  • Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes
    Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
    1 study · 50 participants
    GRADE not reported